PNC Financial Services Group’s Keros Therapeutics KROS Stock Holding History

PNC Financial Services Group’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7K	Buy	999 +650	+186%	+$7.24K	﹤0.01%	4051
2026 Q1	$3.85K	Buy	349 +32	+10%	+$494	﹤0.01%	4377
2025 Q4	$6.45K	Sell	317 -117	-27%	-$2.05K	﹤0.01%	4133
2025 Q3	$6.87K	Sell	434 -386	-47%	-$5.7K	﹤0.01%	4087
2025 Q2	$10.9K	Buy	820 +713	+666%	+$9.63K	﹤0.01%	3832
2025 Q1	$1.09K	Buy	+107	New	+$1.24K	﹤0.01%	4503
2024 Q4	–	Sell	-4	Closed	-$232	–	4870
2024 Q3	$232	Hold	4	–	–	﹤0.01%	4666
2024 Q2	$183	Sell	4 -21	-84%	-$1.13K	﹤0.01%	4678
2024 Q1	$1.66K	Buy	25 +3	+14%	+$178	﹤0.01%	4249
2023 Q4	$875	Buy	+22	New	+$690	﹤0.01%	4338

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PNC Financial Services Group's KROS Position: Q2 2026 in Review

PNC Financial Services Group increased its Keros Therapeutics (KROS) stake by 186% in Q2 2026, buying an estimated $7.24K and bringing the position to 999 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4051.

PNC Financial Services Group first reported a position in KROS in Q4 2023 and has held it in 10 quarters since. The position peaked at $10.9K in Q2 2025. 35 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

PNC Financial Services Group held 999 shares of Keros Therapeutics worth $10.7K as of Q2 2026.
PNC Financial Services Group bought 650 Keros Therapeutics shares in Q2 2026, an estimated $7.24K.
Keros Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4051 holding.
PNC Financial Services Group first reported a position in Keros Therapeutics in Q4 2023 and has held it in 10 quarters since.
PNC Financial Services Group's Keros Therapeutics position peaked at $10.9K in Q2 2025.
35 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.